Boundless Bio, Inc. 8-K

What Happened Boundless Bio, Inc. (BOLD) filed an 8-K (Item 5.07) on June 17, 2026 reporting results from its annual meeting held June 15, 2026. Stockholders elected two Class II directors — James Christensen, Ph.D., and Jennifer Lew — each to serve until the 2029 annual meeting. Stockholders also ratified KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The report was signed by Jessica Oien, Chief Legal Officer and Corporate Secretary.

Key Details

• Meeting date/filed: Annual meeting held June 15, 2026; Form 8-K filed June 17, 2026 (Item 5.07).
• Director election results:
  • James Christensen, Ph.D.: For 9,287,096; Withheld 512,585; Broker non‑votes 5,757,105.
  • Jennifer Lew: For 9,271,084; Withheld 528,597; Broker non‑votes 5,757,105.
• Auditor ratification (KPMG LLP) for FY2026: For 15,376,973; Against 127,747; Abstentions 52,066; no broker non‑votes reported.

Why It Matters These votes confirm board continuity (both Class II directors will serve through the 2029 annual meeting) and maintain audit firm continuity for the coming fiscal year. For investors, the results signal no change in board leadership or independent auditor selection arising from the meeting. Note the presence of substantial broker non‑votes on director matters (uninstructed shares held by brokers), which can affect vote totals for contested or uncontested director elections.